Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Kezar Life Sciences, Inc. - Common Stock
(NQ:
KZR
)
6.340
+0.020 (+0.32%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 19, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kezar Life Sciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
The Week In Charts: How To Make Money While Waiting For Core Trend Trades
↗
July 02, 2022
The real money is in the longer-term core trend trades. However, sometimes those opportunities can be few and far between. This is especially true in a bear market.
Via
Talk Markets
Biotech ETF Tops in June: 5 Stocks That Outperform
↗
June 30, 2022
Although most of the stocks in BBC’s portfolio have delivered strong returns this year so far, a few have gained more than 45%.
Via
Talk Markets
Short Volatility Alert: Kezar Life Sciences, Inc.
↗
June 29, 2022
On Tuesday, shares of Kezar Life Sciences, Inc. (NASDAQ: KZR) experienced volatile short activity. After the activity, the stock price went up +43.43% to $8.29. The overall sentiment for KZR has been...
Via
Benzinga
Wells Fargo Beefs Up Kezar Life Price Target - Read Why
↗
June 28, 2022
Via
Benzinga
Dow Dips Over 400 Points; Crude Oil Rises 2%
↗
June 28, 2022
U.S. stocks turned sharply lower toward the end of trading, with the Dow Jones dropping more than 400 points on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
June 28, 2022
Gainers
Via
Benzinga
Kezar Life Sciences (KZR) Stock Soars on Lupus Trial Results
↗
June 28, 2022
KZR stock is soaring today on news that Kezar Life Sciences' Lupus treatment showed positive results in a clinical trial.
Via
InvestorPlace
Wells Fargo Analyst Has Questions On Kezar's Lupus Nephritis Data Readout, Stock Plunges
↗
May 04, 2022
Via
Benzinga
InflaRx Climbs More Than 40%, Here's 58 Biggest Movers From Yesterday
↗
June 29, 2022
Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) shares climbed 89.8% to close at $2.41 on Tuesday. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade.
Via
Benzinga
Nasdaq Turns Lower; Kezar Life Sciences Shares Jump
↗
June 28, 2022
U.S. stocks pared gains midway through trading, with the Nasdaq Composite and S&P 500 turning lower on Tuesday.
Via
Benzinga
Why Is Ceragon Networks Surging By 19%? 41 Stocks Moving In Tuesday's Mid-Day Session
↗
June 28, 2022
Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) jumped 88.9% to $2.3986. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade.
Via
Benzinga
Occidental Petroleum (OXY) Stock Gets Boost From Yet Another Buffett Buy
↗
June 28, 2022
Occidental Petroleum (OXY) stock is rising on Tuesday after Warren Buffett's Berkshire Hathaway increased its stake in the company.
Via
InvestorPlace
Markets Open Higher; US Goods Gap Narrows To $104.3B In May
↗
June 28, 2022
U.S. stocks traded higher this morning, with the Dow Jones gaining over 350 points on Tuesday.
Via
Benzinga
Why Kezar Life Sciences Stock Is Soaring Today
↗
June 28, 2022
Kezar Life Sciences Inc (NASDAQ: KZR) shares are surging Tuesday after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib.
Via
Benzinga
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
↗
June 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
June 28, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
June 28, 2022
Good morning! It's time for another dive into the biggest pre-market stock movers as we go over the news for Tuesday morning!
Via
InvestorPlace
Why Is Kezar Life Sciences Surging By 78%? 25 Stocks Moving In Tuesday's Pre-Market Session
↗
June 28, 2022
Gainers Kezar Life Sciences, Inc. (NASDAQ: KZR) rose 78% to $10.29 in pre-market trading after the company reported positive topline results from the MISSION Phase 2 clinical trial evaluating...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
June 27, 2022
Gainers
Via
Benzinga
Kezar Life Shares Shoot Higher After Positive Results From Mid-Stage Study Of Kidney Disease Candidate
↗
June 27, 2022
Kezar Life Sciences, Inc. (NASDAQ: KZR) reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN).
Via
Benzinga
After-Hours Action: Why Kezar Life Sciences Stock Is Soaring
↗
June 27, 2022
Kezar Life Sciences Inc (NASDAQ: KZR) shares are surging in Monday's after-hours session after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib.
Via
Benzinga
Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
June 27, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Billionaire Israel Englander Is Betting Big on These 5 Stocks
↗
June 24, 2022
Millennium Management's Israel Englander is in focus after the billionaire's fund purchased several stocks this month.
Via
InvestorPlace
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 03, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
3 Biotech Stocks to Buy Before They Boom
↗
June 01, 2022
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations.
Via
InvestorPlace
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
↗
May 30, 2022
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for...
Via
Benzinga
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 05, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
81 Biggest Movers From Yesterday
↗
May 05, 2022
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday.
Via
Benzinga
Mid-Afternoon Market Update: Crude Oil Jumps 5%; Fed Boosts Interest Rates By 0.5%
↗
May 04, 2022
U.S. stocks traded mixed toward the end of trading, after the Federal Reserve announced its policy decision.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today